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It has been postulated that the patient with atopic 
dermatitis has defective beta adrenergic receptor func-
tion. However, a more generalized defect is suggested by 
the observation that cyclic AMP generation is dimin-
ished in these patients following stimulation with both 
isoproterenol and PGE1• To determine the nature of this 
abnormality, we measured beta adrenergic receptor 
binding directly on polymorphonuclear leukocyte mem-
branes using the radiolabeled beta adrenergic antago-
nist (-) ['IH] dihydroalprenolol (DHA). DHA binding was 
studied in 6 mild and 9 moderate-to-severe atopic der-
matitis patients, and 8 normal controls using a subsatur-
ating concentration of DHA (0.5 nM) to estimate receptor 
affinity and a saturating concentration of DHA (30 mM) 
to determine the total number of receptors per cell. 
No significant differences (p > .05) were found in the 
total number of receptors per PMN between the control 
population (805 ± 95) and the mild atopic dermatitis 
patients (745 ± 91) or the moderate to severe group (621 
± 79). In addition, no significant differences in receptor 
affinity were found among any of the 3 study groups. 
These findings suggest that beta receptor binding in 
atopic dermatitis is normal. Reduced cyclic AMP gener-
ation in atopic dermatitis PMN leukocytes would appear 
to be due to a defect distal to the beta adrenergic receptor 
itself. 
Szentivanyi [1] has postulated that atopic disease is charac-
terized by a blockade of the beta adrenergic receptor resulting 
in an imbalance with increased alpha adrenergic and cholinergic 
receptor function. Clinical and laboratory evidence suggest that 
an imbalance of the autonomic nervous system exists in atopic 
dermatitis· and that this phenomenon may be important in the 
pathogenesis of the disease [2]. Recently, impaired beta adre-
nergic function in peripheral blood leukocytes of patients with 
active atopic dermatitis has been reported [3,4]. Busse and Lee · 
[3] reported decreased cyclic adenosine 3,5 monophosphate 
(cyclic AMP ) responses to isoproterenol in granulocytes and 
lymphocytes from eczema patients, while Parker, Kennedy, and 
Eisen [4] showed a decreased response to both isoproterenol 
and prostaglandin (PG) E" in leukocytes and purified lympho-
cytes in patient with severe, but not mild atopic dermatitis. 
These studies suggest that if defective generation of cyclic AMP 
truly exists in atopic disease, the defect may be distal to the 
beta adrenergic receptor since a decreased response was seen 
following stimulation with PGE" as well as isoproterenoL 
In order to more clearly identify the abnormality in the 
pathway to cyclic AMP generation, one must assess the frrst 
step in the sequence, that of hormone binding to the beta 
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adrenergic receptor. We have recently developed a method for 
the direct measurement of the number and affmity of beta 
adrenergic receptors on polymorphonuclear (PMN) membranes 
using the tritiated beta adrenergic antagonist (-) ['JH] dihy-
droalprenolol (DHA) [5]. PMN may be more suitable than 
lymphocytes for clinical studies of beta adrenergic receptors, 
because PMN appear to be a more homogeneous population 
than are lymphocytes [6-8]. In this study we report our findings 
of beta adrenergic receptor binding in mild and moderate to 
severe atopic dermatitis patients compared to a healthy control 
group. 
MATERIALS AND METHODS 
Subjects 
A total of 15 patients with atopic dermatitis and 8 normal controls 
were studied. The diagnosis of atopic dermatitis was based on well-
defined clinical and historical features as previously described [2]. 
Extent (E) and severity (S) of disease were graded on a scale of 1-5 and 
the product of the 2 grades (E X S) was the overall indicator of clinical 
involvement [9). Thus, a score of 25 would indicate maximally severe 
generalized erythroderma. Patients with E X S scores of 10 or under 
were considered to have mild atopic dermatitis while those with scores 
greater than 10 were defined as having moderate to severe atopic 
dermatitis. Subjects were divided into three categories as follows. 
Group I-control population: There were 8 control subjects who 
had no evidence of atopic dermatit is or other atopic diseases. These 
subjects included 5 males and 3 females with a mean age of 36.9 yr for 
the group. 
Group II-mild atopic derm.a~itis (clinical score :510): This group 
consisted of 6 patients, 2 males and 4 females with a mean age of 31.8 
yr. 
Group Ill-moderate-to-severe atopic dermatitis (clinical score 
> 10): There were 9 patients in this group, 3 males and 6 females, with 
a mean age of 34.1 yr. 
Selective Criteria 
The subjects in all 3 groups were carefully screened to exclude 
individuals with active viral infection, those receiving adrenocorticos-
teroids, cardiac glycosides, antihypertensive or other sympathomi-
metic-containing medication. 
Preparation of Polym.orphonuclear (PMN) Particulates 
Sixty ml of heparinized blood was obtained from each subject in the 
study. Blood was centrifuged on Ficoll-Hypaque density gradient ac-
cording to the method of Boyum [10]. The pellets conta ining erythro-
cytes and granulocytes were diluted 1:2 with phosphate buffered saline 
(PBS) and then mixed with an equa l volume of 3% (wt/vol) high 
molecular weight Dextran (1'250 Pharmacia Fine Chemicals, Piscata-
way, New Jersey) in PBS. 
The erythrocytes were a llowed to settle for 25 min at room temper-
ature, and the Dextran separation procedure was repeated since this 
second separation increases the PMN yield. The supernatant fraction 
was then exposed to 0.2% NaCI for 20 seconds in order to lyse contam-
inating erythrocytes; 1.6% NaCI was used to restore isotonicity, and the 
cells were centr ifuged at 350 xg for 10 min. The cellular pellet was 
resuspended in a few ml of PBS and the number of cells was counted. 
PMN were 90 ± 3.5% (mean ± SD) with the remainder of the cells less 
than 5% lymphocytes, less than 5% eosinophils, less than 1 % basophils 
a nd less than 1% monocytes. Less than 1 platelet was found for every 
nucleated cell counted. The cellular suspension was made hypotonic 
with 0.2% NaCl for 30 to 40 min at 4°C, a nd then centrifuged at 450 
xg for 10 min. The pellet was resuspended in incubation buffer [50 mM 
Tris H CL (pH 8.1 at 4°C), 10 mM MgCb] at a density equivalent to '108 
ce lls/ml. The suspension was subjected to freeze thawing and then 
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h omogenized with 8 to 10 strokes in a T en-Broeck homogenizer prior 
to use in the binding assay. All particulates were used in the binding 
assay immediately after thawing and homogenization. 
Beta·Adrenerg ic R eceptor Binding Assay 
In a previous study [5], we found that the dissociation constant (KD) 
for DHA binding to PMN particulates was 1 to 5 nM and, thus, 
satuI'ation of the binding sites occurred at 10 to 30 nM DHA. In the 
present study we used two DHA concentrations, 0.5 nM and 30 nM for 
a ll s ubjects. Because of the yield of PMN particulate protein it was 
impossible to study DHA binding at more than 2 DHA concentrations. 
W e chose 0.5 nM as a sUbsaturating concentration and 30 nM as a 
concentration that wou ld refl ect the total number of DHA binding 
s ites. DHA (New England Nuclear) specific activity was 49 Ci/mmol. 
Binding assays contained in the total volume of incubation buffer of 
0.15 ml: DHA, PMN membranes obtained from 0.75 x 107 cells (which 
corresponds to 440 f.Lg protein) , 1 mM ascorbic acid, 0.3 mM catechol, 
a nd 0.1 mM phentolamine. Ascorbic acid is included to block oxidation 
of catecholamines, and catechol and phentolamine to inhibit nonspe-
cific binding [11 ,12]. These agents did not affect specific binding. 
Samples were incubated at 37°C for 15 min. Incubations were te rmi-
n ated by rapidly diluting samples with 2 ml of ice-cold incubation 
buffer and then immediately fLItering the mixture through a glass fLI ter 
(Gelman A/ E). The fLIters were presoaked in incubation buffer con-
taining 0.1 mM (±)-propranolol to block nonspecific binding of radio-
activity to the fll ters. The fllters were rapidly (10 seconds) washed with 
15 m l of ice-cold incubation buffer and the radioactivity of the dried 
filters was determined in a liquid scintillation system ( 'H) efficiency = 
45% ). Specific binding represents the total amount of radioactive DHA 
bound minus the amount bound in the presence of 1 p,M (±)-propranolol 
and was greater than 80% at 0.5 nM and about 50% at 30 nM of the total 
aIDount bound. All data shown in this paper are specific binding. 
Specific binding was linear with protein at the concentration used in 
t h ese experiments. All samples were run as duplicates and these differed 
from each other by less than 15%. Protein was measured by the method 
of Lowry, Rosebrough, and Farr [13] using bovine serum albumin 
standards. 
Analy .• is 0,. Bindin.g Data 
The quanti ty of DHA binding in fmol/mg protein was determined. 
S ince J mg of our p31'ticulate preparation is derived from 1.8 X 107 
PMN, the number of receptors per cell was calculated by the formula: 
Number of receptors 
moles of DHA bound 6.02 x 102:1 molecules 
----.,:.,...----- X -----,---
cell mole 
Each group was comp31'ed with the others using a nonpaired Student's 
test analysis for significant differences in binding. 
RESULTS 
Although the ratio of males to females was slightly different 
in Group I (5:3) compared to Groups II and III (2:4 and 3:6 
respectively ) we have previously shown no difference in DHA 
binding between males and females (14]. In addition, the groups 
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appear reasonably well age matched with mean ages of 36.9 
years for Group I compared to 31.8 years in Group II and 34.1 
years in Group III. DHA binding in the normal subjects (Group 
I) was compared with the mild atopic dermatitis patients 
(Group II) and those with moderate-to-severe disease (Group 
III) both at the low DHA concentration (0.5 nM) and at the 
saturation DHA concentration (30 nM) in the Table. Statistical 
analysis revealed no significant difference (p >.05) between the 
control population and either atopic dermatitis group. This was 
true at 0.5 nM when one compares Group I at 9.7 ± 1.2 fmol/mg 
protein (mean ± SEM) with Group II at 9.5 ± 1.7 or Group III 
with 9.2 ± 0.9, and at the 30 nM DHA concent ration where the 
control group bound 25.4 ± 3.0 fmol/mg protein compared to 
23.5 ± 3.0 and 19.6 ± 2.5 for th e mild and moderate-to-severe 
atopic dermatitis groups respectively. The total number of 
receptors was calculated for each group. Group I PMN had 805 
± 95 beta adrenergic r eceptors per cell compared to 745 ± 91 
a nd 621 ± 79 PMN receptors for Group II and III. Again, no 
statistical difference (p >.05) was found between any of t he 
group comparisons. Finally, if one uses the percentage of the 
total binding at 0.5 nM DHA as an indication of receptor affinity, 
no significant differences are found between groups. 
DISCUSSION 
In this report we have found that the PMN beta adrenergic 
receptor in atopic dermatitis cannot be distinguished statisti-
cally from a normal control population regardless of the disease 
severity. However, since DHA dose r esponse curves were not 
performed on atopic dermatit is patients because of the blood 
requi.rement we have not ruled out the possibility of abnormal 
DHA binding kinetics in this populat ion. Although this question 
cannot be presently resolved from this study, we feel our data 
certainly suggest that the total number of receptors and the 
estimate of receptor affinity in atopic dermatitis ar e both nor-
mal. Patient 3 in Group III has low binding, but he too falls 
within 2 standard deviations of t he mean DHA binding found 
in our laboratory (14). Although the number of subjects is 
small , these data ar e very similar to t hose we have r ecently 
reported in a larger number of patients with bronchial asthma 
[14,15]' Asthmatics have normal binding regardless of the se-
verity of their illness unless th ey are receiving adrenergic drug 
therapy. Patients with severe atopic dermatitis appear to have 
normal binding too, although Parker, Kennedy, and Eisen [4] 
clearly showed significantly decreased cyclic AMP responses to 
both isoproterenol and PGE, in leukocytes from patients with 
severe but not mild disease. Although these data appear to be 
in conflict a t first, t hey may be in fact consistent with a defect 
in the coupling of the membrane-hormone receptor wit h the 
enzym e adenylate cyclase rat her than an abnormality of the 
receptor itself. This would account for the decreased cyclic 
DHA binding (fmol/mgm protein) 
G,'oup I-Normals Group Il- Mild atopic dermatitis Group III- Moderate to severe atopic derma t.itis 
Subject 0.5 nM 30 nM Subject 0.5 nM 30 nM Clinical" Subject 0.5 nM 30 nM Clinical score SCOre 
38 M 7.8 14.6 38 M ILl 22.2 4 42 F 10.9 16.9 12 
35 M 13.6 40.3 26 F 11.0 20.6 6 28 F 10.9 23.4 12 
41 M 15.3 27.6 25 F 15.6 37.0 4 26M 7.1 10.0 20 
23 M 8.8 17.3 46 F 11.4 22.3 9 31 F 11.7 21.1 20 
31 F 8.0 22.1 27 F 4.0 24.0 4 21 M 8.3 21.3 16 
34 F 4.1 22.2 29 M 3.8 14.8 6 44 M 11.0 13.9 20 
31 F 10.2 32.8 54 F 11.6 36.2 25 
56 M 9.6 26.6 27 F 5.4 16.6 25 
34 F 5.8 16.8 25 
Mean 9.7 25.4 Mean 9.5 23.5 Mean 9.2 19.6 
SEM 1.2 3.0 SEM 1.7 3.0 SEM 0.9 2.5 
ph {vi;. Grp I >.10 >.10 > .05 >.05 
vs. Grp II >.10 >.10 >.10 > .10 
n Clinical atopic dermatitis score determined by extent and severity of lesions (see Material and Methods). 
b P values determined by nonpaired student t-test. 
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AMP response not only to isoproterenol, but PGE] as well. In 
addition, in bronchial asthma an analogous situation may exist 
explaining the diminished granulocytes cyclic AMP responsive-
ness to both histamine [16] and isoproterenol [17]. 
Atopic dermatitis would appear to provide an excellent model 
for study of the proposed abnormality of the beta adrenergic 
system since, unlike asthma, systemic drugs are seldom neces-
sary and abnormalities in leukocyte function including the 
granulocyte have been identified [18]. Measurement of beta 
receptor binding and adenylate cyclase activity on the same 
membrane preparation in a larger number of patients should 
help elucidate the nature of the diminished cyclic AMP respon-
siveness. Hopefully these studies will improve our understand-
ing of the pathogenesis of atopic dermatitis as well as other 
atopic diseases. 
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Announcement 
Practical Skin Pathology 
A course in skin pathology, sponsored by the departments of dermatology and pathology, New York 
Medical College-Metropolitan Hospital Center; the American Society of Clinical Pathology; and the 
American Society of Dermatopathology, will be given on August 26 through 31, 1979 at Grossinger's, 
Grossinger, New York. The course will be a comprehensive, practical review, and update of dermatopath-
ology. It will consist of formal lectures, question and answer periods, supervised microscope sessions, 
opportunity for optional independent study of microscopic slides, and a post test period with in depth 
panel discussions. The course is accredited for 39 hours in category 1 toward the AAD Continuing 
Education Award. For further information, please write to: Martin H . Brownstein, M.D., Skin Pathology 
COUJ'se, Two Jordan Drive, Great N eck, New York, 11021. 
